Clinical Trial Update: Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma [Phase 2]

View source ↗

Summary

The document notes a Phase 2 trial evaluating Zanzalintinib in combination with pembrolizumab for select subtypes of advanced or metastatic soft-tissue sarcoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase 2, Zanzalintinib | Phase 2 | Status: RECRUITING